Latest Biotechnology, Pharmaceutical and Healthcare News from PharmPro

09:59 EDT 28th June 2017 | BioPortfolio

Here are the most relevant search results for "PharmPro" found in our extensive news archives from over 250 global news sources.

More Information about PharmPro on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmPro for you to read. Along with our medical data and news we also list PharmPro Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmPro Companies for you to search.

Showing News Articles 1–25 of 3,900+ from PharmPro

Wednesday 28th June 2017

Microneedle Patch for Flu Vaccination Found Safe in Phase 1 Trial

NewsPhase 1 clinical trial shows safety and immunogenicity of microneedle patch for flu vaccination for the first time.

MerLion & Dstl Given Grant for Chemical & Biological Defense Research

NewsMerLion and Dstl awarded DTRA grant to explore the use of finafloxacin against biological threat agents.

Vaccine to Slow Cancer Growth Closer to Human Trials

NewsA more targeted and affordable cancer treatment vaccine with wide ranging potential is being tested on dogs ahead of human trials.

Lots of Hospira's Potassium Phosphate & Succinylcholine Chloride Recalled Due to Compounding Sterility Concern

NewsPharMEDium Services issues voluntary nationwide recall of specific lots of potassium phosphate and succinylcholine chloride due to a lack of sterility assurance.

Kenya 1st in Africa to Use Generic of Current AIDS Drug

NewsOfficials say Kenya is the first country in Africa to introduce a generic version of the current drug of choice for people living with HIV.

Tuesday 27th June 2017

US Does Not Need Warrant to Subpoena Oregon Drug Data

NewsAccording to a new ruling, the U.S. Drug Enforcement Agency does not need a court order to subpoena a prescription drug database kept by the state of Oregon.

Genentech’s Hemophilia A Drug Reduces Bleed Rate in Phase 3 Studies

NewsGenentech’s emicizumab showed positive results in Phase III studies (HAVEN 1 and HAVEN 2) in hemophilia A with inhibitors.

DQSA Is Essential for Compounded Drug Quality, Says FDA Commissioner

NewsStatement from FDA Commissioner Scott Gottlieb, M.D., on the importance of the Drug Quality and Security Act and overseeing the safety of compounded drugs.

Roche Pulls Ahead in Oncology, Expected to Remain Market Leader Until 2023

NewsRoche will remain oncology market leader to 2023, in an increasingly fragmented but growing therapy area, says GBI Research.

OSE Temporarily Halts Patient Enrollment in Phase 3 Lung Cancer Study

NewsOSE Immunotherapeutics announces temporary pause of patient accrual while continuing treatment for patients already enrolled in Phase 3 clinical trial of Tedopi in advanced lung cancer.

TraceLink to Fully Manage DSCSA Administrative Tasks for Hospitals and Pharmacies

NewsTraceLink announces end-to-end administration for Product Track, alleviating time-intensive DSCSA compliance tasks for U.S. hospitals and pharmacies.

Alma and Delphi Extend Partnership Aimed at Autoimmune Diseases

NewsAlma Bio Therapeutics and Delphi Genetics extend strategic alliance on plasmid DNA drugs. Partnership will advance development of drugs aimed at treating underlying cause of uncontrolled inflammation in autoimmune diseases.

Monday 26th June 2017

Pharmacy Boss Blamed for Meningitis Outbreak Gets 9 Years

NewsBarry Cadden, co-owner of a compounding pharmacy deemed responsible for the deaths of 76 people in a national meningitis outbreak, tearfully apologized to the victims on Monday and was sentenced to nine years in prison.

'Pharma Bro' Defies Advice to Keep Quiet Before Fraud Trial

NewsWith his federal securities fraud trial set to begin, Martin Shkreli has blatantly defied his attorneys' advice to lay low. The former pharmaceutical CEO has been preening for cameras and trolling on social media, potentially complicating his defense.

FDA Approves Novartis Targeted Therapy for Non-Small Cell Lung Cancer

NewsNovartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC). Approval provides first targeted treatment in the U.S. specifically for the disease.

Pharmacy Group Members Seek to Expand Value-Based Contracting

NewsAcademy of Managed Care Pharmacy (AMCP) Partnership Forum attendees create action plans to advance value-based contracting. The plan would move away from a fee-for-service model toward a pre-approved payment criteria.

FDA Approves Anticoagulant for Prevention of Venous Thromboembolism

NewsU.S. FDA approves Bevyxxa (betrixaban) first and only anticoagulant for hospital and extended duration prevention of venous thromboembolism (VTE) in acutely ill medical patients.

U.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients

NewsU.S. FDA approves Bevyxxa (betrixaban) first and only anticoagulant for hospital and extended duration prevention of venous thromboembolism (VTE) in acutely ill medical patients.

Friday 23rd June 2017

Lack of Sterility Assurance Leads to Secondary Recall of Syringe

NewsSuccinylcholine Chloride 20mg/mL 5mL syringe by Fagron Sterile Services: Recall—potential lack of sterility assurance. The product is manufactured by Hospira Inc., a Pfizer company, and repacked by Fagron Sterile Services.

Prosecutors Seek 35-Year Term in Deadly Meningitis Outbreak

NewsBarry Cadden will be sentenced Monday on charges of racketeering, conspiracy and fraud in the 2012 fungal meningitis outbreak that killed more than 60 people and sickened more than 700 others in 20 states.

Gilead Receives Positive Opinion for Chronic Hepatitis C Treatments

NewsEuropean CHMP adopts positive opinion for Gilead’s Vosevio (sofosbuvir/velpatasvir/voxilaprevir) for the treatment of all chronic hepatitis C genotypes.

Novartis Trial Shows Durable Remission Rates for Children with Leukemia

NewsNovartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL. Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months.

FDA Approves Rituxan Hycela for Subcutaneous Injection in Certain Blood Cancers

NewsFDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers. Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan.

Marine-Derived Anticancer Drugs Show Continuing Progress

NewsA patent study on the great new hope emerging from marine derived anticancer drugs. The patents revealed that chemically modified versions of marine derived microtubule targeting agents have positioned them as future anticancer blockbusters.

Thursday 22nd June 2017

Biodegradable Plastics Made from Sugar & Carbon Dioxide: To Replace Polycarbonates?

NewsPlastic made from sugar and carbon dioxide.Contributed Author: 

Quick Search

News Quicklinks